Table 1.
Characteristics of the 13 cohorts from nine countries that participated in the analyses
| Cohort | No. of patients, no. of deaths and no. lost to follow-up | Crude mortality rate per 100 person-years of follow-upa (95% CI) | No. of women (%) | No. with history of injection drug use at baseline (%) | No. with AIDS at baseline (%) | Median CD4 cells/μL at 6 months (IQR) | No. with viral load ≤500 copies/ml at 6 months |
|---|---|---|---|---|---|---|---|
| A | 279, 23, 73 | 1.97 (1.31–2.96) | 93 (33) | 34 (12) | 47 (17) | 296 (143–487) | 214 (77) |
| B | 648, 22, 80 | 0.88 (0.58–1.34) | 148 (23) | 78 (12) | 78 (12) | 433 (261–589) | 535 (83) |
| C | 4380, 154, 732 | 0.87 (0.74–1.01) | 1082 (25) | 171 (4) | 972 (22) | 340 (210–500) | 3788 (86) |
| D | 672, 73, 32 | 2.29 (1.82–2.89) | 81 (12) | 295 (44) | 286 (43) | 320 (180–500) | 498 (74) |
| E | 434, 17, 95 | 1.01 (0.63–1.62) | 103 (24) | 23 (5) | 138 (32) | 270 (160–410) | 348 (80) |
| F | 1055, 34, 370 | 0.90 (0.65–1.27) | 110 (10) | 40 (4) | 408 (39) | 364 (216–552) | 773 (73) |
| G | 13 645, 474, 4890 | 0.87 (0.79–0.96) | 4209 (31) | 1599 (12) | 2981 (22) | 312 (177–468) | 10 202 (75) |
| H | 1442, 72, 193 | 1.12 (0.89–1.41) | 307 (21) | 221 (15) | 279 (19) | 285 (160–432) | 1190 (83) |
| I | 2252, 66, 880 | 0.73 (0.58–0.93) | 630 (28) | 797 (35) | 372 (17) | 385 (216–572) | 1656 (74) |
| K | 1705, 41, 208 | 0.90 (0.66–1.22) | 405 (24) | 529 (31) | 462 (27) | 313 (174–491) | 1420 (83) |
| L | 655, 5, 99 | 0.29 (0.12–0.69) | 162 (25) | 12 (2) | 171 (26) | 309 (180–485) | 560 (85) |
| M | 291, 14, 71 | 1.08 (0.64–1.82) | 55 (19) | 57 (20) | 85 (29) | 288 (183–447) | 240 (82) |
| N | 2477, 139, 432 | 1.31 (1.11–1.54) | 777 (31) | 544 (22) | 459 (19) | 321 (183–484) | 2115 (85) |
| All cohorts | 29 935, 1134, 8155 | 0.95 (0.91–1.02) | 8162 (27) | 4400 (15) | 6738 (23) | 322 (185–489) | 23 539 (79) |
a
Calculation of time at risk started at 6 months.
CI = confidence interval.